Senolytics

Senolytics is a 6.5–7.0/10 fit for longevity, healthspan, cellular senescence, especially for readers who can match the protocol to age, disease context, drug interactions, and whether the protocol is supervised. The best evidence anchors are Shimizu et al. 2025, which RCT n=110 randomized; no statistically significant overall primary or secondary endpoint changes; male subgroup CD8+ high-SA-beta-gal signal only, and Guan et al. 2024, which 83 included articles; 78 animal studies and 5 human studies; human dietary-senotherapeutic evidence limited with unclear risk of bias. Senolytics are compounds intended to clear senescent cells. That makes the intervention most useful when the reader wants the studied outcome, accepts the evidence limits, and can track whether the response shows up.

✅ Best for: Adults over 50 with measurable signs of age-related decline, chronic low-grade inflammation, reduced physical function, fibrotic conditions, metabolic disease, or high suspected senescent-cell burden. Biohackers who want to explore the senolytic mechanism without dasatinib's prescription-drug risk. People who understand that F+Q is a low-cost experiment, not a proven longevity therapy. Older users who can review CYP3A4 and anticoagulant interactions before a short dosing window. Patients considering D+Q only under clinician supervision, especially where early human pilots such as Justice 2019 or Hickson 2019 are relevant to their condition.

❌ Avoid if: You are under 40 with no signs of accelerated aging. You have active cancer or recent cancer history unless your oncologist explicitly clears it. You take warfarin, a direct oral anticoagulant, high-dose aspirin, or high-risk CYP3A4-dependent medications. You are pregnant, breastfeeding, preparing for surgery, dealing with severe liver or kidney disease, or expecting Phase 3-level proof. Avoid D+Q without medical supervision. No FDA approval, Cochrane synthesis, USPSTF recommendation, NICE endorsement, or IPF society guideline supports senolytics for healthy aging as of the 2026-05-03 audit.